First experience with BAK-free travoprost 0.004% in topical glaucoma medication

First experience with BAK-free travoprost 0.004% in topical glaucoma medication

Ahmed Salah Gado, Tamer Ahmed MackyDepartment of Ophthalmology, Cairo University, Cairo, EgyptObjectives: Benzalkonium chloride (BAK)-free travoprost 0.004% (Travatan Z®, Alcon Laboratories, Inc, Fort Worth, TX) is a new formulation that was developed with the aim of creating a formulati...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Gado AS, Macky TA
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2011
Materias:
Ophthalmology
RE1-994
Acceso en línea:https://doaj.org/article/6af4ffd9396743919e562666c8ceecd5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:6af4ffd9396743919e562666c8ceecd5
record_format dspace
spelling oai:doaj.org-article:6af4ffd9396743919e562666c8ceecd52021-12-02T05:25:15ZFirst experience with BAK-free travoprost 0.004% in topical glaucoma medication1177-54671177-5483https://doaj.org/article/6af4ffd9396743919e562666c8ceecd52011-12-01T00:00:00Zhttp://www.dovepress.com/first-experience-with-bak-free-travoprost-0004-in-topical-glaucoma-med-a8857https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Ahmed Salah Gado, Tamer Ahmed MackyDepartment of Ophthalmology, Cairo University, Cairo, EgyptObjectives: Benzalkonium chloride (BAK)-free travoprost 0.004% (Travatan Z®, Alcon Laboratories, Inc, Fort Worth, TX) is a new formulation that was developed with the aim of creating a formulation of travoprost that would maintain the intraocular pressure (IOP)-lowering efficacy and have an improved overall safety profile, particularly improved ocular surface tolerability.Methods: Thirty newly diagnosed primary open-angle glaucoma (POAG) patients were treated with BAK-free travoprost 0.004%. IOP readings were recorded at baseline before initiating treatment, at 4–6 weeks, and after 12 weeks of starting treatment. In addition, patient demographics, subjective symptoms (ie, burning, foreign-body sensation, itching, and stinging), and objective clinical signs such as conjunctival hyperemia were collected. Subjective symptoms were evaluated using a four-point scale ranging from “no symptoms,” “mild symptoms,” “moderate symptoms” to “severe symptoms.” As for clinical signs, severity of conjunctival hyperemia was evaluated. All other adverse events were collected.Results: BAK-free travoprost 0.004% provided an IOP decrease in all patients, with an overall mean of 28.3 ± 2.1 mmHg at baseline to a mean of 18.7 ± 1.6 mmHg at 4–6 weeks, and a mean of 18.4 ± 1.4 mmHg after 12 weeks. Both subjective symptoms and objective clinical signs were very few after treatment.Conclusion: The results demonstrate that BAK-free travoprost 0.004% is an effective, well tolerated, and safe medication in POAG patients.Keywords: primary open-angle glaucoma, POAG, benzalkonium chloride, TravatanGado ASMacky TADove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2012, Iss default, Pp 1-4 (2011)
institution DOAJ
collection DOAJ
language EN
topic Ophthalmology
RE1-994
spellingShingle Ophthalmology
RE1-994
Gado AS
Macky TA
First experience with BAK-free travoprost 0.004% in topical glaucoma medication
description Ahmed Salah Gado, Tamer Ahmed MackyDepartment of Ophthalmology, Cairo University, Cairo, EgyptObjectives: Benzalkonium chloride (BAK)-free travoprost 0.004% (Travatan Z®, Alcon Laboratories, Inc, Fort Worth, TX) is a new formulation that was developed with the aim of creating a formulation of travoprost that would maintain the intraocular pressure (IOP)-lowering efficacy and have an improved overall safety profile, particularly improved ocular surface tolerability.Methods: Thirty newly diagnosed primary open-angle glaucoma (POAG) patients were treated with BAK-free travoprost 0.004%. IOP readings were recorded at baseline before initiating treatment, at 4–6 weeks, and after 12 weeks of starting treatment. In addition, patient demographics, subjective symptoms (ie, burning, foreign-body sensation, itching, and stinging), and objective clinical signs such as conjunctival hyperemia were collected. Subjective symptoms were evaluated using a four-point scale ranging from “no symptoms,” “mild symptoms,” “moderate symptoms” to “severe symptoms.” As for clinical signs, severity of conjunctival hyperemia was evaluated. All other adverse events were collected.Results: BAK-free travoprost 0.004% provided an IOP decrease in all patients, with an overall mean of 28.3 ± 2.1 mmHg at baseline to a mean of 18.7 ± 1.6 mmHg at 4–6 weeks, and a mean of 18.4 ± 1.4 mmHg after 12 weeks. Both subjective symptoms and objective clinical signs were very few after treatment.Conclusion: The results demonstrate that BAK-free travoprost 0.004% is an effective, well tolerated, and safe medication in POAG patients.Keywords: primary open-angle glaucoma, POAG, benzalkonium chloride, Travatan
format article
author Gado AS
Macky TA
author_facet Gado AS
Macky TA
author_sort Gado AS
title First experience with BAK-free travoprost 0.004% in topical glaucoma medication
title_short First experience with BAK-free travoprost 0.004% in topical glaucoma medication
title_full First experience with BAK-free travoprost 0.004% in topical glaucoma medication
title_fullStr First experience with BAK-free travoprost 0.004% in topical glaucoma medication
title_full_unstemmed First experience with BAK-free travoprost 0.004% in topical glaucoma medication
title_sort first experience with bak-free travoprost 0.004% in topical glaucoma medication
publisher Dove Medical Press
publishDate 2011
url https://doaj.org/article/6af4ffd9396743919e562666c8ceecd5
work_keys_str_mv AT gadoas firstexperiencewithbakfreetravoprost0004intopicalglaucomamedication
AT mackyta firstexperiencewithbakfreetravoprost0004intopicalglaucomamedication
_version_ 1718400417778368512

Ejemplares similares